Abstract
Bestatin has no clinical toxicity. It increases the number of T cells and enhances NK cell activity. The optimal dose of bestatin was thought to range from 30–100 mg/day/body, and 200 mg/day/body often decreased T-cell number.
The clinical effects were as follows:
-
1)
Bestatin alone: possible cure in one case of residual penile tumor after bleomycin treatment; marked regression in two cases of skin metastasis of mammary carcinoma.
-
2)
Radiation and bestatin: complete regression in three cases of Virchow’s nodes.
-
3)
Pepleomycin and bestatin: complete regression in one case of metastatic skin adenocarcinoma.
-
4)
Possible favorable effect of bestatin against esophageal carcinoma in combination with radiation and bleomycin.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Aoike A, Tanaka Y, Hosokawa T, Yamaguchi N, Kawai K (to be published) Effect of bestatin on natural killer activity. In: Small molecular immunomodulators of microbial origin. Japan Scientific Societies Press, Tokyo
Aoyagi T, Suda H, Nagai M, Ogawa K, Suzuki J, Takeuchi T, Umezawa H (1976) Aminopeptidase activities on the surface of mammalian cells. Biochim Biophys Acta 452:131–143
Cooperative Study Group on Bestatin (1979) In: Interim report, part 1, Cooperative Study Group on Bestatin, Tokyo, pp 1–120, 1979; part 2, Cooperative Study Group on Bestatin, Tokyo, pp 1–93
Ichikawa T, Isurugi K (1978) Effect of a new immunomodulator, bestatin, in the treatment of urogenital malignancies. Read before the 12th International Congress of Cancer, Buenos Aires, October
Kondo T, Watanabe N, Tachibana T (1978) Rapid and simple assay in microtest plate for enumeration of human T and B lymphocyte populations. Strides Med 107:312–314
Tachibana T, Yoshida A (1974) Determination of human T and B lymphocyte populations in microtest plate (an improved method). In: The Japanese Society for Immunology (eds) Experimental methods in immunology A (in Japanese), pp 907–914
Umezawa H (1977) Recent advances in bioactive microbial secondary metabolites. Jpn J Antibiot 30 [Suppl]: 138–163
Umezawa H, Aoyagi T, Suda H, Hamada M, Takeuchi T (1976) Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes. J Antibiot (Tokyo) 29:97–99
Umezawa H, Ishizuka M, Aoyagi T, Takeuchi T (1976) Enhancement of delayed-type hypersensitivity by bestatin, an inhibitor of aminopeptidase B and leucine aminopeptidase. J Antibiot (Tokyo) 29:857–859
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1980 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Oka, S. (1980). A Review of Clinical Studies of Bestatin. In: Mathé, G., Muggia, F.M. (eds) Cancer Chemo- and Immunopharmacology. Recent Results in Cancer Research, vol 75. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81491-4_20
Download citation
DOI: https://doi.org/10.1007/978-3-642-81491-4_20
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81493-8
Online ISBN: 978-3-642-81491-4
eBook Packages: Springer Book Archive